En/Whats-New

Catch up with the latest at Lotus Labs – as and when it happens. Featured here are updates on news and events. Read on…
 

10/07/2015   Lotus Labs has successfully completed 2nd inspection by MHRA, UK.
Lotus Labs has successfully completed 2nd inspection by MHRA, UK.

Lotus Labs has  successfully completed 2nd  inspection by MHRA, UK.


26/06/2015   Lotus Labs has successfully completed inspection by National Pharmaceutical Control Bureau (BPFK) , Ministry of Health, Malaysia and has been registered as an approved Bioequivalence Evaluation Centre till June 2018.
Lotus Labs has successfully completed inspection by National Pharmaceutical Control Bureau (BPFK) , Ministry of Health, Malaysia and has been registered as an approved Bioequivalence Evaluation Centre till June 2018.

Lotus Labs has  successfully completed inspection by National Pharmaceutical Control Bureau (BPFK) , Ministry of Health, Malaysia and has been registered as an approved Bioequivalence Evaluation Centre till June 2018.

Click here to view the Document

04/03/2015   Lotus Labs has received its renewed ANVISA permission for all the Bangalore facilities, which is valid till 24th Oct 2017 for the conduct of clinical, analytical, statistical and bioavailability studies.
Lotus Labs has received its renewed ANVISA permission for all the Bangalore facilities, which is valid till 24th Oct 2017 for the conduct of clinical, analytical, statistical and bioavailability studies.

Lotus Labs has received its renewed ANVISA permission for all the Bangalore facilities, which is valid till 24th Oct 2017 for the conduct of clinical, analytical, statistical and bioavailability studies.


30/10/2014   Lotus Labs at Global Generics & Biosimilars Awards 2014.
Lotus Labs at Global Generics & Biosimilars Awards 2014.

Lotus Labs supported the new initiative of Generics bulletin to recognize the tremendous work done by executives in the global generics and biosimilars industries by being part of the event and sponsoring an award. The event was held at Paris on October 7th 2014 during CPHI Worldwide.
Based on company submissions and nominations, the top three entries for the company of the year award were AMCo, Hikma and Julphar pharma.
In creating the Global Generics & Biosimilars Awards 2014, Lotus Labs sponsored the Award - Company of the year - EMEA and announced Hikma Pharmaceuticals as the winner of the sponsored category. The award recognizes excellent performance across a range of business activities and was won in strong competition against a number of leading EMEA pharmaceutical companies. 
More than 150 invited guests – including several CEOs and other senior managers – from the industries’ leading players gathered to network and celebrate at an evening Awards ceremony.
Mr. Hari Sankar, Managing Director- Lotus Labs seen below announcing the winner and presenting the award to the Hikma representative.


30/10/2014   Lotus Labs has received its renewed ANVISA permission on 24th Oct 2014 for all the four facilities, which is valid till 24th Oct 2015 for the conduct of clinical, analytical, statistical and bioavailability studies.
Lotus Labs has received its renewed ANVISA permission on 24th Oct 2014 for all the four facilities, which is valid till 24th Oct 2015 for the conduct of clinical, analytical, statistical and bioavailability studies.

Lotus Labs has received its renewed ANVISA permission on 24th Oct 2014 for all the four facilities, which is valid till 24th Oct 2015 for the conduct of clinical, analytical, statistical and bioavailability studies.
 


30/10/2014   Lotus has successfully completed its 16th USFDA inspection in October 2014 increasing the total number of audits faced till date to 62.
Lotus has successfully completed its 16th USFDA inspection in October 2014 increasing the total number of audits faced till date to 62.

Lotus has successfully completed its 16th      USFDA inspection in October 2014 increasing the total number of audits faced till date to 62.


19/08/2014   Lotus Labs has got its CAP (College of American Pathologists) accreditation renewed till year 2016.
Lotus Labs has got its CAP (College of American Pathologists) accreditation renewed till year 2016.

Lotus Labs has got its CAP (College of American Pathologists) accreditation renewed till year 2016.

Click here to view the Document

05/09/2013   Lotus has successfully completed USFDA audit in September 2013.
Lotus has successfully completed USFDA audit in September 2013.

Lotus has successfully completed USFDA audit in September 2013


11/06/2013   Lotus Labs has been recognized as an approved Bioequivalence Evaluation Center by National Pharmaceutical Control Bureau (BPFK) , Ministry of Health, Malaysia.
Lotus Labs has been recognized as an approved Bioequivalence Evaluation Center by National Pharmaceutical Control Bureau (BPFK) , Ministry of Health, Malaysia.

Bioequivalence studies performed at Lotus Labs from the period of October 2013 to October 2015 would be received by BPFK

Click here to view the Document

25/04/2013   Lotus has successfully completed WHO audit in April 2013 increasing the total number of audits faced till date to 58
Lotus has successfully completed WHO audit in April 2013 increasing the total number of audits faced till date to 58

Lotus has successfully completed WHO audit in April 2013 increasing the total number of audits faced till date to 58


21/12/2012   Lotus has successfully completed MHRA audit in October 2012 and ANVISA audit in December 2012.
Lotus has successfully completed MHRA audit in October 2012 and ANVISA audit in December 2012.

 Lotus has successfully completed MHRA audit in October 2012 and ANVISA audit in December 2012.


21/12/2012   Lotus has actively participated in CPHI 2012 @ Madrid and AAPS 2012 @ Chicago. Please find the attached photographs for the same.
Lotus has actively participated in CPHI 2012 @ Madrid and AAPS 2012 @ Chicago. Please find the attached photographs for the same.

 Lotus has actively participated in CPHI 2012 @ Madrid and AAPS 2012 @ Chicago. Please find the attached photographs for the same.

 

 


21/12/2012   Lotus has successfully completed the process of Self Identification Number with FDA. Please append the attached word document for DUNS numbers.
Lotus has successfully completed the process of Self Identification Number with FDA. Please append the attached word document for DUNS numbers.

 Lotus has successfully completed the process of Self Identification Number with FDA. Please append the attached word document for DUNS numbers.

Click here to view the Document

08/06/2012   Lotus Labs has been recognized as an approved Bioequivalence Evaluation Centre by National Pharmaceutical Control Bureau ( BPFK), Ministry of Heath, Malaysia .
Lotus Labs has been recognized as an approved Bioequivalence Evaluation Centre by National Pharmaceutical Control Bureau ( BPFK), Ministry of Heath, Malaysia .

Lotus Labs has been recognized as an approved Bioequivalence Evaluation Centre by National Pharmaceutical Control Bureau ( BPFK), Ministry of Heath, Malaysia . 

Bioequivalence studies performed in Lotus Labs from the period of May 2010 to May 2013 would  be received by  BPFK.

Click here to View document


08/05/2012   Lotus Labs has been recognized as one of the “Best Enterprises” in the field of Clinical Research 2012
Lotus Labs has been recognized as one of the “Best Enterprises” in the field of Clinical Research 2012

 Lotus Labs has been recognized as one of the “Best Enterprises” in the field of Clinical Research, India, by the European Business Assembly ,Socrates Committee, Oxford ,UK,  2012.

          


01/01/2012   Regulatory audits in 2011
Regulatory audits in 2011
  •  DCGI – 4 audits
  • USFDA – 1 audit (12th Time)
  • WHO – 1 audit  (8th Time)
  • MOH, Turkey - 1 audit  ( 3rd Time)
A total of 7 regulatory audits were successfully completed in 2011 at Lotus. The cumulative audits faced at Lotus are 51.
 
Also, Lotus sites which participated in 2 Clinical trials submitted to USFDA faced regulatory audits on 2 occasions.